Tassos Gianakakos

Mr. Gianakakos has served as Chief Executive Officer of MyoKardia (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, since October 2013. He joined MyoKardia from MAP Pharmaceuticals (acquired by Allergan in March 2013), where he was most recently senior vice president and chief business officer. Prior to MAP, Mr. Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., where he served as president and senior vice president, business development, and global head of Codexis’ Pharmaceuticals Business Unit. Before forming Codexis, Mr. Gianakakos was director of business development at Maxygen. Mr. Gianakakos began his career as a process engineer within Merck & Co.’s vaccine division. Mr. Gianakakos holds B.Sc. degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an M.Sc. in biotechnology from Northwestern University and an M.B.A. from Harvard Business School.